Asthma in the era of SARS CoV-2 virus.
Agamemnon BakakosAnastasia KrompaPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2021)
Despite the lack of evidence for higher susceptibility and/or mortality in relation to COVID-19, all asthmatic patients, whether treated with inhaled bronchodilators/corticosteroids or even biologics, should maintain their controller therapy without making any alterations.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- coronavirus disease
- chronic kidney disease
- ejection fraction
- lung function
- chronic obstructive pulmonary disease
- respiratory syndrome coronavirus
- cystic fibrosis
- cardiovascular events
- stem cells
- coronary artery disease
- patient reported outcomes
- risk factors
- patient reported